Monitoring for new-onset atrial fibrillation (NOAF) should be considered as a strategy after transcatheter aortic valve replacement (TAVR) as a common and risky complication, though whether it is a causal factor or a marker of “sicker patients” remains unclear, according to a new meta-analysis.